Lumida
/ALMS
⌘K
Alumis Inc

Alumis Inc

ALMS
$9.18USD-7.27%-0.72 today

MARKET CAP

1.2B

P/E (TTM)

FWD P/E

DAY RANGE

$9 – $10

52W RANGE

$4
$31

AI Summary

Stalk
Sell NowMedium

ALMS remains entrenched in a Stage 4 decline with price trading well below all major EMAs and SMAs, anchoring a bearish medium-term bias. Despite an extreme oversold RSI and a Post-Capitulation signal hinting at supply absorption, there is no clear stabilization above key EMAs. Short-term conditions favor selling into any corrective bounce at the 9/20 EMA zone or on a breakdown of the $9.00–$9.50 consolidation support. Execution is targeted now via Sell Now, participating in continuation on failed rallies or support breakdown.

  • Envudeucitinib ONWARD3 trial: 75% PASI 90 & 54% PASI 100 at 48 weeks
  • $502.3M cash & equivalents support operations into Q4 2027
  • Q2 2026 revenue $1.7M down 37% YoY vs. $3.47M consensus
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2025TREND
Sales, Adj.$24.1M
YoY %
P / Sales34.5x
EV / Sales35.4x
Gross Profit, Adj.$24.1M
YoY %
Margin %100.0%
EV / Gross Profit35.4x
EBITDA, Adj.$-450.3M
YoY %-51.3%
Margin %-1872.4%
EV / EBITDA-1.9x
EBIT$-453.8M
YoY %-50.9%
Margin %-1886.9%
EV / EBIT-1.9x
Net Income$-243.3M
YoY %+17.3%
Net Margin-1011.7%
EPS (GAAP)-$2.86
YoY %+72.4%